Hemophilia therapy: the future has begun
The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms...
Uloženo v:
| Vydáno v: | Haematologica (Roma) Ročník 105; číslo 3; s. 545 - 553 |
|---|---|
| Hlavní autor: | |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Italy
Ferrata Storti Foundation
01.03.2020
|
| Témata: | |
| ISSN: | 0390-6078, 1592-8721, 1592-8721 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms of greater safety and availability in the 1990s, when the first recombinant coagulation factors were produced. This meant that, instead of only treating episodic bleeding events, prophylaxis regimens could be implemented as a preventive measure. Following the demonstration of its superiority in the frame of two randomized clinical trials, prophylaxis became evidence-based standard of care. In high-income countries, these achievements have led to a patients' life expectancy being extended to close to that of the general male population. Alongside this, the last decade has witnessed further spectacular therapeutic progress, such as the availability of coagulation factors with a longer plasma half-life that allow for wider intervals between treatment. Moreover, new therapeutic products based on new mechanisms other than the replacement of the deficient factor, have become available (emicizumab) or are at an advanced stage of development. This review celebrates the success story of hemophilia care, while also discussing current limitations, issues and as yet unmet needs. The prospects of cure by means of gene therapy are also outlined. |
|---|---|
| AbstractList | The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms of greater safety and availability in the 1990s, when the first recombinant coagulation factors were produced. This meant that, instead of only treating episodic bleeding events, prophylaxis regimens could be implemented as a preventive measure. Following the demonstration of its superiority in the frame of two randomized clinical trials, prophylaxis became evidence-based standard of care. In high-income countries, these achievements have led to a patients' life expectancy being extended to close to that of the general male population. Alongside this, the last decade has witnessed further spectacular therapeutic progress, such as the availability of coagulation factors with a longer plasma half-life that allow for wider intervals between treatment. Moreover, new therapeutic products based on new mechanisms other than the replacement of the deficient factor, have become available (emicizumab) or are at an advanced stage of development. This review celebrates the success story of hemophilia care, while also discussing current limitations, issues and as yet unmet needs. The prospects of cure by means of gene therapy are also outlined. The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms of greater safety and availability in the 1990s, when the first recombinant coagulation factors were produced. This meant that, instead of only treating episodic bleeding events, prophylaxis regimens could be implemented as a preventive measure. Following the demonstration of its superiority in the frame of two randomized clinical trials, prophylaxis became evidence-based standard of care. In high-income countries, these achievements have led to a patients' life expectancy being extended to close to that of the general male population. Alongside this, the last decade has witnessed further spectacular therapeutic progress, such as the availability of coagulation factors with a longer plasma half-life that allow for wider intervals between treatment. Moreover, new therapeutic products based on new mechanisms other than the replacement of the deficient factor, have become available (emicizumab) or are at an advanced stage of development. This review celebrates the success story of hemophilia care, while also discussing current limitations, issues and as yet unmet needs. The prospects of cure by means of gene therapy are also outlined.The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and factor IX (FIX) provided efficacious treatment of bleeding in patients with hemophilia A and B. This positive scenario was consolidated in terms of greater safety and availability in the 1990s, when the first recombinant coagulation factors were produced. This meant that, instead of only treating episodic bleeding events, prophylaxis regimens could be implemented as a preventive measure. Following the demonstration of its superiority in the frame of two randomized clinical trials, prophylaxis became evidence-based standard of care. In high-income countries, these achievements have led to a patients' life expectancy being extended to close to that of the general male population. Alongside this, the last decade has witnessed further spectacular therapeutic progress, such as the availability of coagulation factors with a longer plasma half-life that allow for wider intervals between treatment. Moreover, new therapeutic products based on new mechanisms other than the replacement of the deficient factor, have become available (emicizumab) or are at an advanced stage of development. This review celebrates the success story of hemophilia care, while also discussing current limitations, issues and as yet unmet needs. The prospects of cure by means of gene therapy are also outlined. |
| Author | Mannucci, Pier Mannuccio |
| Author_xml | – sequence: 1 givenname: Pier Mannuccio surname: Mannucci fullname: Mannucci, Pier Mannuccio |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32060150$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxS1URLeFb4DQHnvJMv4Te90DEqqAVqrEBc7W2J5sXCXx4iRI_fZk2S6iHDh5ZL_3e9a8C3Y25IEYe8thI6VQ71ukHqfcbQRwuxFScClesBWvrai2RvAztgJpodJgtufsYhwfAARYa16xcylAA69hxa5uqc_7NnUJ11NLBfeP14dh3czTXGjd4rj2tJuH1-xlg91Ib57OS_b986dvN7fV_dcvdzcf76ugjJoqHgNxTtI0litAIK-DNxY8QYxWG-DCQ43BN4JQ-UhGBsRtYyPFrVYoL9ndkRszPrh9ST2WR5cxud8XuewclimFjpxFkhGCCAKj0nWz9VFzrbSJTQO1Dwvrw5G1n31Py8-GqWD3DPr8ZUit2-WfzoCyUtcL4OoJUPKPmcbJ9WkM1HU4UJ5HJ2RdL0LQZpG--zvrT8hp1Yvg-igIJY9jocaFNOGU8iE6dY6DO_TqTr26Q6_u2OtiVv-YT_z_2n4BqUGqTg |
| CitedBy_id | crossref_primary_10_1016_j_rpth_2023_102161 crossref_primary_10_1055_s_0042_1756188 crossref_primary_10_1007_s13312_024_3140_1 crossref_primary_10_1080_17474086_2021_1923476 crossref_primary_10_1096_fba_2025_00200 crossref_primary_10_2147_PPA_S326282 crossref_primary_10_1182_bloodadvances_2021006119 crossref_primary_10_1016_j_omtm_2021_04_016 crossref_primary_10_1186_s12929_024_01035_4 crossref_primary_10_1182_bloodadvances_2022008989 crossref_primary_10_1186_s12959_023_00511_5 crossref_primary_10_3389_fped_2023_1273639 crossref_primary_10_2147_JMDH_S363177 crossref_primary_10_1016_j_jtha_2023_01_010 crossref_primary_10_1111_hae_14780 crossref_primary_10_1111_hae_15112 crossref_primary_10_1111_hae_14661 crossref_primary_10_1111_hae_14660 crossref_primary_10_24287_1726_1708_2024_23_4_58_61 crossref_primary_10_1002_rth2_12508 crossref_primary_10_1111_hae_14268 crossref_primary_10_1007_s12325_023_02570_6 crossref_primary_10_4103_ijnmr_ijnmr_142_24 crossref_primary_10_1007_s12015_024_10799_z crossref_primary_10_1016_j_rpth_2024_102670 crossref_primary_10_1111_hae_70112 crossref_primary_10_1080_16078454_2024_2316540 crossref_primary_10_1111_hae_14807 crossref_primary_10_1016_j_socscimed_2025_117937 crossref_primary_10_1016_j_ijpharm_2020_120037 crossref_primary_10_1177_20406207221145627 crossref_primary_10_1111_ejh_14309 crossref_primary_10_2147_JBM_S359510 crossref_primary_10_3390_genes15121522 crossref_primary_10_1111_hex_13404 crossref_primary_10_2147_JBM_S418818 crossref_primary_10_3390_life14121640 crossref_primary_10_3390_ph15080911 crossref_primary_10_2196_48359 crossref_primary_10_1016_j_blre_2021_100912 crossref_primary_10_1016_j_rpth_2023_100159 crossref_primary_10_2147_JBM_S260923 crossref_primary_10_1016_j_rpth_2024_102559 crossref_primary_10_1016_j_nmni_2024_101470 crossref_primary_10_1177_20406207241245511 crossref_primary_10_1056_NEJMe2024545 crossref_primary_10_1111_jth_15444 crossref_primary_10_2147_JBM_S490588 crossref_primary_10_1016_S0140_6736_24_02139_1 crossref_primary_10_1111_hae_14531 crossref_primary_10_1111_jth_15682 crossref_primary_10_1182_bloodadvances_2024013900 crossref_primary_10_2147_PPA_S355627 crossref_primary_10_3390_ijms24108584 crossref_primary_10_3390_pr8121676 crossref_primary_10_1055_s_0044_1787662 crossref_primary_10_1055_s_0044_1796629 crossref_primary_10_1111_scd_12713 crossref_primary_10_1111_hae_14769 crossref_primary_10_1136_bcr_2020_241154 crossref_primary_10_3390_hematolrep16020019 crossref_primary_10_1007_s12325_023_02559_1 crossref_primary_10_1111_hae_14001 crossref_primary_10_1111_hae_70015 crossref_primary_10_25122_jml_2022_0103 crossref_primary_10_1016_j_medcli_2021_04_031 crossref_primary_10_1002_rth2_12655 crossref_primary_10_1182_blood_2023021864 crossref_primary_10_3390_ph14010054 crossref_primary_10_1016_j_rpth_2023_100173 crossref_primary_10_1111_ijlh_14258 crossref_primary_10_1177_20406207231165857 crossref_primary_10_1016_j_jtha_2023_12_018 crossref_primary_10_1016_j_hoc_2021_07_008 crossref_primary_10_1111_hae_14755 crossref_primary_10_1111_hae_14116 crossref_primary_10_3390_diagnostics12122937 crossref_primary_10_3389_fmed_2024_1345496 crossref_primary_10_1016_j_ajps_2025_101068 crossref_primary_10_1007_s11427_021_1952_5 crossref_primary_10_1016_S0140_6736_23_00284_2 crossref_primary_10_1111_hae_14476 crossref_primary_10_1002_jev2_12240 crossref_primary_10_1111_hae_14511 crossref_primary_10_2478_jhp_2025_0004 crossref_primary_10_56712_latam_v6i3_4022 crossref_primary_10_1016_j_blre_2021_100852 crossref_primary_10_1016_j_medcle_2021_04_013 crossref_primary_10_1016_j_jtha_2023_12_027 crossref_primary_10_2147_PPA_S470091 crossref_primary_10_1080_17474086_2023_2184341 crossref_primary_10_1111_hae_14589 crossref_primary_10_3390_jcm13010225 crossref_primary_10_1056_NEJMoa2119913 crossref_primary_10_1016_j_omtn_2023_03_008 crossref_primary_10_2147_PPA_S394216 crossref_primary_10_1016_j_bcmd_2022_102663 crossref_primary_10_1016_j_jtha_2024_07_007 crossref_primary_10_1055_a_2358_0853 crossref_primary_10_2478_jhp_2025_0003 crossref_primary_10_1055_a_2621_9749 crossref_primary_10_1111_hae_14983 crossref_primary_10_3390_jpm12040519 crossref_primary_10_1055_s_0043_1778103 crossref_primary_10_3390_life14121568 crossref_primary_10_1016_j_ymthe_2024_02_010 crossref_primary_10_1016_j_jtha_2023_10_005 crossref_primary_10_1016_j_blre_2020_100737 crossref_primary_10_1111_jth_14955 crossref_primary_10_2147_JMDH_S430984 crossref_primary_10_1111_hae_14610 crossref_primary_10_2478_jhp_2025_0012 crossref_primary_10_1186_s13023_022_02313_w crossref_primary_10_1111_hae_70067 crossref_primary_10_19127_bshealthscience_1092964 crossref_primary_10_1111_hae_70064 crossref_primary_10_1080_09638288_2021_2018053 crossref_primary_10_1182_blood_2020009217 crossref_primary_10_12968_hmed_2020_0016 crossref_primary_10_1016_j_tracli_2020_12_004 crossref_primary_10_1080_17474086_2021_1963706 crossref_primary_10_1182_blood_2024027008 crossref_primary_10_1080_17474086_2023_2293092 crossref_primary_10_1016_S2352_3026_23_00037_6 crossref_primary_10_3390_ph15101183 crossref_primary_10_52645_MJHS_2024_2_06 crossref_primary_10_1080_14712598_2022_2002842 crossref_primary_10_1111_ejh_14135 crossref_primary_10_1038_s41467_023_39986_1 crossref_primary_10_1016_j_blre_2021_100828 crossref_primary_10_1055_a_2071_0477 crossref_primary_10_1016_j_revmed_2024_05_002 crossref_primary_10_1016_j_intimp_2025_114218 crossref_primary_10_1002_ajh_26018 crossref_primary_10_1002_rth2_12695 crossref_primary_10_3390_medicines9030021 crossref_primary_10_3390_life14050623 crossref_primary_10_1111_hae_14315 crossref_primary_10_2147_JBM_S446204 crossref_primary_10_3390_ijms25115741 crossref_primary_10_1111_hae_14439 crossref_primary_10_1111_jth_15226 crossref_primary_10_1111_ejh_13676 crossref_primary_10_1182_bloodadvances_2021006016 crossref_primary_10_1111_hae_14792 crossref_primary_10_1016_j_hoc_2022_03_009 crossref_primary_10_1111_hae_15005 crossref_primary_10_1111_ijlh_14171 crossref_primary_10_1111_hae_14313 crossref_primary_10_1111_hae_14796 crossref_primary_10_1111_hae_15125 |
| ContentType | Journal Article |
| Copyright | Copyright© 2020 Ferrata Storti Foundation. Copyright© 2020 Ferrata Storti Foundation 2020 |
| Copyright_xml | – notice: Copyright© 2020 Ferrata Storti Foundation. – notice: Copyright© 2020 Ferrata Storti Foundation 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3324/haematol.2019.232132 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1592-8721 |
| EndPage | 553 |
| ExternalDocumentID | oai_doaj_org_article_9ae3d0c2c2ad465f8bd616467dff05bc PMC7049365 32060150 10_3324_haematol_2019_232132 |
| Genre | Journal Article Review |
| GroupedDBID | --- 29I 2WC 53G 5GY 5RE 5VS AAFWJ AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GROUPED_DOAJ H13 HYE KQ8 OK1 OVT P2P RHI RNS RPM SJN TFS TR2 UDS W8F WOQ WOW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c474t-1dce11e37f9140a0eb6cb790be0dd967012b05acbf2ea4bde73caa8f9ded864a3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 172 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000518368400022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0390-6078 1592-8721 |
| IngestDate | Fri Oct 03 12:42:38 EDT 2025 Thu Aug 21 14:09:58 EDT 2025 Fri Jul 11 08:07:53 EDT 2025 Mon Jul 21 05:56:33 EDT 2025 Sat Nov 29 06:32:56 EST 2025 Tue Nov 18 22:00:56 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright© 2020 Ferrata Storti Foundation. https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-1dce11e37f9140a0eb6cb790be0dd967012b05acbf2ea4bde73caa8f9ded864a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/9ae3d0c2c2ad465f8bd616467dff05bc |
| PMID | 32060150 |
| PQID | 2355936067 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9ae3d0c2c2ad465f8bd616467dff05bc pubmedcentral_primary_oai_pubmedcentral_nih_gov_7049365 proquest_miscellaneous_2355936067 pubmed_primary_32060150 crossref_citationtrail_10_3324_haematol_2019_232132 crossref_primary_10_3324_haematol_2019_232132 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-03-00 20200301 2020-03-01 |
| PublicationDateYYYYMMDD | 2020-03-01 |
| PublicationDate_xml | – month: 03 year: 2020 text: 2020-03-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Italy |
| PublicationPlace_xml | – name: Italy |
| PublicationTitle | Haematologica (Roma) |
| PublicationTitleAlternate | Haematologica |
| PublicationYear | 2020 |
| Publisher | Ferrata Storti Foundation |
| Publisher_xml | – name: Ferrata Storti Foundation |
| SSID | ssj0020997 |
| Score | 2.6322684 |
| SecondaryResourceType | review_article |
| Snippet | The success story of hemophilia care first began in the 1970s, when the availability of plasma-derived concentrates of coagulation factor VIII (FVIII) and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 545 |
| SubjectTerms | Blood Coagulation Factors Blood Coagulation Tests Centenary Review Factor IX - genetics Factor VIII - genetics Genetic Therapy Hemophilia A - therapy Humans Male |
| Title | Hemophilia therapy: the future has begun |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32060150 https://www.proquest.com/docview/2355936067 https://pubmed.ncbi.nlm.nih.gov/PMC7049365 https://doaj.org/article/9ae3d0c2c2ad465f8bd616467dff05bc |
| Volume | 105 |
| WOSCitedRecordID | wos000518368400022&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: DOA dateStart: 19940101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEB-0iPgi2voRW0sEEV9ik-wmu-tbWyx90OKDwr2F_Zh4hTZXendC__vO7OaOngh96VtINuwyM8nMb2f2NwAfW5RG69AX1tmmkBpdoYMuC9TkPpFDboxdS76rszM9mZifd1p9cU1YogdOgjswFkUofe1rG2Tb9NqFljmxVOj7snGe_74U9azA1Ai1-DxozB8YAkfkBdOhOUHRw8HUMhnqjNMOlflCAUUl6g2nFLn7_xdw_ls3eccRnbyA52MEmR-mlb-ERzhsw87hQLNd3uSf8ljTGTfLt-HpjzF1vgOfT_FydsXbJzZPh65uvvJFnlhF8qmd5w7_LIdX8Pvk26_j02Jsk1B4qeSiqGg9VYVC9YbQki3Rtd4pUzosQzCtIhfkysZ619dopQuohLdW9yZg0K204jVsDbMB30LuaqulwZoZZSRFNo7RmEMUfePaYFQGYiWnzo8c4tzK4qIjLMHS7VbS7Vi6XZJuBsX6ravEoXHP-CNWwXosM2DHG2QX3WgX3X12kcGHlQI7-mI4DWIHnC3nNEnDbQzJTWfwJil0PZWomZ-mKTNQG6reWMvmk-F8Glm5FWEt0TbvHmLxu_CsZlwfa932YGtxvcT38MT_XZzPr_fhsZro_WjwtzCkBTI |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hemophilia+therapy%3A+the+future+has+begun&rft.jtitle=Haematologica+%28Roma%29&rft.au=Mannucci%2C+Pier+Mannuccio&rft.date=2020-03-01&rft.eissn=1592-8721&rft.volume=105&rft.issue=3&rft.spage=545&rft_id=info:doi/10.3324%2Fhaematol.2019.232132&rft_id=info%3Apmid%2F32060150&rft.externalDocID=32060150 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon |